Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01905592
Title A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients (BRAVO)
Recruitment Completed
Gender both
Phase Phase III
Variant Requirements No
Sponsors Tesaro, Inc.
Indications

Her2-receptor negative breast cancer

Therapies

Niraparib

Age Groups: adult | senior
Covered Countries USA | ITA | FRA | ESP | CAN | BEL


No variant requirements are available.